Childhood Mortality After Mass Distribution of Azithromycin: A Secondary Analysis of the PRET Cluster-randomized Trial in Niger.
Kieran S O'Brien, Sun Y Cotter, Abdou Amza...
https://pubmed.ncbi.nlm.nih.gov/29561511/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-08-17
3300000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the impact of azithromycin mass drug administration MDA on child survival and antimicrobial resistance AMR in Niger. This adaptive platform trial focuses on monitoring under-5 mortality rates and AMR as the azithromycin program expands nationwide. The study aims to track mortality trends over time relative to global reduction targets and to assess the ongoing effectiveness and risks associated with azithromycin use in children. Participants receive azithromycin distribution targeted to children aged 1 to 59 months, delivered door-to-door by community health workers. The study compares three groups continuous azithromycin distribution for four years, delayed distribution beginning after two years, and stopping distribution after two years. This design includes monitoring and re-randomization every two years to adapt the intervention based on observed outcomes. During the study, participants undergo surveillance for mortality and AMR through nasopharyngeal and rectal swabs collected at two- and four-year intervals. Researchers measure all-cause mortality, prevalence of macrolide resistance, genetic resistance markers, and frequency of infectious clinic visits. The trial includes verbal approvals from communities and caregivers, and tracks program costs and reported illnesses over time, with a total duration extending to four years of treatment and monitoring.
CONDITIONS
Azithromycin for Child Survival in Niger II
A
Andrea R Picariello, MPH
E
Elodie Lebas
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
Centre de recherche et interventions en santé publique (CRISP)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years
Children receive azithromycin distribution delivered door-to-door by community health workers according to assigned study groups: continuous, delayed, or stopping after two years.
Regular visits during drug distribution
Duration - 4 years
Researchers collect samples and data on mortality and antimicrobial resistance at 2- and 4-year intervals to assess outcomes and safety.
Sample collection and clinical assessments at 2 and 4 years
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Kieran S O'Brien, Sun Y Cotter, Abdou Amza...
https://pubmed.ncbi.nlm.nih.gov/29561511/Ali Sié, Mamadou Ouattara, Mamadou Bountogo...
https://pubmed.ncbi.nlm.nih.gov/38231623/Thuy Doan, Lee Worden, Armin Hinterwirth...
https://pubmed.ncbi.nlm.nih.gov/33176084/Ahmed M Arzika, Abdou Amza, Sani Ousmane...
https://pubmed.ncbi.nlm.nih.gov/41709349/Jeremy D Keenan, Robin L Bailey, Sheila K West...
https://pubmed.ncbi.nlm.nih.gov/29694816/T Doan, A Hinterwirth, L Worden...
https://pubmed.ncbi.nlm.nih.gov/31406349/Jeremy D Keenan, Ahmed M Arzika, Ramatou Maliki...
https://pubmed.ncbi.nlm.nih.gov/31981558/Dennis L Chao, Ahmed M Arzika, Amza Abdou...
https://pubmed.ncbi.nlm.nih.gov/38100110/Jeremy D Keenan, Berhan Ayele, Teshome Gebre...
https://pubmed.ncbi.nlm.nih.gov/21427395/Ahmed M Arzika, Abdou Amza, Sani Ousmane...
https://pubmed.ncbi.nlm.nih.gov/40585143/University of California, San Francisco
Lead Sponsor
Centre de recherche et interventions en santé publique (CRISP)
Collaborating Sponsor